Q32 Bio Inc.

06/08/2026 | Press release | Distributed by Public on 06/08/2026 14:31

Initial Statement of Beneficial Ownership (Form 3)

FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Atlas Venture Opportunity Fund Ill, L.P.
2. Date of Event Requiring Statement (Month/Day/Year)
05/26/2026
3. Issuer Name and Ticker or Trading Symbol
Q32 Bio Inc. [QTTB]
(Last) (First) (Middle)
ATLAS VENTURE, 300 TECHNOLOGY SQUARE, 8TH FLOOR
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
_____ Officer (give title below) __X__ Other (specify below)
See Remarks
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)
CAMBRIDGE, MA 02139
6. Individual or Joint/Group Filing (Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 625,000 D(1)
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Atlas Venture Opportunity Fund Ill, L.P.
ATLAS VENTURE
300 TECHNOLOGY SQUARE, 8TH FLOOR
CAMBRIDGE, MA 02139
See Remarks
Atlas Venture Associates Opportunity III, L.P.
300 TECHNOLOGY SQ., 8TH FLOOR
CAMBRIDGE, MA 02139
See Remarks
Atlas Venture Associates Opportunity III, LLC
300 TECHNOLOGY SQ., 8TH FLOOR
CAMBRIDGE, MA 02139
See Remarks

Signatures

Atlas Venture Opportunity Fund III, L.P., By: Atlas Venture Associates Opportunity III, L.P., its general partner, By: Atlas Venture Associates Opportunity III, LLC, its general partner, By: /s/ Ommer Chohan, Chief Financial Officer 06/08/2026
**Signature of Reporting Person Date
Atlas Venture Associates Opportunity III, L.P., By: Atlas Venture Associates Opportunity III, LLC, its general partner, By: /s/ Ommer Chohan, Chief Financial Officer 06/08/2026
**Signature of Reporting Person Date
Atlas Venture Associates Opportunity III, LLC, By: /s/ Ommer Chohan, Chief Financial Officer 06/08/2026
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The shares are owned directly by Atlas Venture Opportunity Fund III, L.P. ("AVOF III"). Atlas Venture Associates Opportunity III, L.P. ("AVAO III LP") is the general partner of AVOF III. Atlas Venture Associates Opportunity III, LLC ("AVAO III LLC") is the general partner of AVAO III LP. Each of AVAO III LP and AVAO III LLC disclaims beneficial ownership of the securities held by AVOF III, except to the extent of its pecuniary interest therein, if any.

Remarks:
The Reporting Persons are under common control with other entities affiliated with Atlas Venture who, together with the Reporting Persons, collectively beneficially own in the aggregate greater than 10% of the outstanding common stock of the Issuer. The Reporting Persons may be deemed to be members of a "group" with such other entities for purposes of Section 13 of the Exchange Act. However, the Reporting Persons disclaim such group membership, and this Form 3 shall not be deemed an admission that the Reporting Persons are members of a group for purposes of Section 13 of the Exchange Act or for any other purposes.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Q32 Bio Inc. published this content on June 08, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 08, 2026 at 20:31 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]